Stockreport

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Cybin Inc. Common Shares  (CYBN) 
PDF - Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for [Read more]